12 terminated. 12 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Terminated 12 |
| Phase 2 | 2 | Terminated 2 |
Follow Mitomycin: new trials by email Literature Review of Mitomycin trials Research Report on Mitomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UGN-102, TURBT - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Terminated | UroGen Pharma Ltd. | 282 | 2021-02-19 | 2024-06-06 |
| Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. Synergo® RITE + MMC - Bladder Cancer, Bladder Neoplasm | Phase 3 | Terminated | Medical Enterprises Ltd. | 5 | 2019-04-04 | 2020-04-15 |
| Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Nanoxel®M, Mitomycin-C - Non Muscle Invasive Bladder Cancer | Phase 3 | Terminated | Samyang Biopharmaceuticals Corporation | 36 | 2017-01-01 | 2019-08-30 |
| Therapeutic Instillation of Mistletoe abnobaVISCUM 900, Mitomycin C - Superficial Bladder Cancer | Phase 3 | Terminated | Abnoba Gmbh | 174 | 2015-04-01 | 2026-05-22 |
| A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA MEP - Nasopharyngeal Carcinoma | Phase 3 | Terminated | National Health Research Institutes, Taiwan | 10 | 2014-12-14 | 2025-08-19 |
| Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer CG0070 Adenovirus Vector, Control Arm: Quadruple Choice - Transitional Cell Carcinoma, Bladder Cancer | Phase 2 / Phase 3 | Terminated | CG Oncology, Inc. | 22 | 2014-03-01 | 2021-04-14 |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer EN3348, Mitomycin C - Bladder Neoplasm, Neoplasm Recurrence, Local | Phase 3 | Terminated | Bioniche Life Sciences Inc. | 84 | 2010-11-01 | 2017-08-24 |
| Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer bevacizumab, cetuximab, FOLFIRI regimen - Colorectal Cancer | Phase 3 | Terminated | Alliance for Clinical Trials in Oncology | 340 | 2010-08-01 | 2024-12-27 |
| Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients Mitomycin C (MMC), Bacillus Calmette-Guerin (BCG) - Bladder Cancer | Phase 3 | Terminated | Memorial Sloan Kettering Cancer Center | 50 | 2009-09-01 | 2015-11-20 |
| Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer cisplatin, fluorouracil, mitomycin C - Anal Cancer | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 88 | 2003-07-01 | 2012-09-24 |
| Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer mitomycin C, conventional surgery - Bladder Cancer | Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 58 | 2002-05-01 | 2012-09-24 |
| Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655) FOLFIRI regimen, cisplatin, doxorubicin hydrochloride - Colorectal Cancer, Metastatic Cancer | Phase 3 | Terminated | American College of Radiology Imaging Network | 2001-11-01 | 2020-12-02 |
Urinary Bladder Neoplasms (6) · Carcinoma, Transitional Cell (4) · Non-Muscle Invasive Bladder Neoplasms (3) · Carcinoma in Situ (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Neoplasms (2) · Adenoviridae Infections (1) · Anus Neoplasms (1) · Disease (1) · Epstein-Barr Virus Infections (1) · Mycobacterium Infections (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Neoplasm Recurrence, Local (1)
European Organisation for Research and Treatment of Cancer - EORTC (2) · Abnoba Gmbh (1) · Alliance for Clinical Trials in Oncology (1) · American College of Radiology Imaging Network (1) · Bioniche Life Sciences Inc. (1) · CG Oncology, Inc. (1) · Medical Enterprises Ltd. (1) · Memorial Sloan Kettering Cancer Center (1) · National Health Research Institutes, Taiwan (1) · Samyang Biopharmaceuticals Corporation (1) · UroGen Pharma Ltd. (1)
United States (7) · Germany (3) · Netherlands (3) · Belgium (2) · Egypt (2) · Italy (2) · Poland (2) · Serbia (2) · Bulgaria (1) · Canada (1) · Estonia (1) · France (1) · Georgia (1) · Israel (1) · Latvia (1)
Alex W Yeung, MBBS (1) · Alexander Stojadinovic, MD (1) · Chia-Jui Yen Yen, MD. PhD (1) · Ching-Yun Hsieh, MD (1) · Guido Dalbagni, MD (1) · Hsiao-Hui Tsou, PhD (1) · Ja Hyeon Ku (1) · Jean-Francois Bosset, MD (1) · Jin-Ching Lin, MD, PHD (1) · Jin-Ching Lin, MD, PhD (1) · Jochen Hess, Prof. Dr. (1) · Michael A O'Donnell, MD (1) · Michael C. Soulen, MD (1) · Sandip Prasad, MD (1) · Stella Yu-Chen Tsai, MD (1)
2023 (1), U01CA079778 (1), U01CA080098 (1)